肿瘤细胞治疗研究
英文原题：Advances in the treatment of Hodgkin lymphoma: Current and future approaches.
Advances in the treatment of Hodgkin lymphoma: Current and future approaches.
它约占美国诊断出的淋巴瘤的十分之一，并包括两种亚型：经典型霍奇金淋巴瘤（cHL），占HL病例的大多数，以及结节性淋巴细胞为主型霍奇金淋巴瘤，约占霍奇金淋巴瘤病例的5%。
霍奇金淋巴瘤（HL）是一种罕见淋巴瘤，具有独特的组织学、免疫表型和临床特征，约占美国确诊淋巴瘤的十分之一，包括两种亚型：经典型霍奇金淋巴瘤（cHL）占大多数，结节性淋巴细胞为主型霍奇金淋巴瘤约占5%。本文综述聚焦cHL。总体而言，一线化疗可治愈多数患者，可选择联合放疗。然而，部分患者一线方案治疗后复发或无应答；对化疗敏感的cHL，标准治疗模式是大剂量化疗后接受自体造血干细胞移植（AHSCT）。近年来，靶向免疫疗法彻底改变了cHL治疗；除了多种正在探索的新型药物，嵌合抗原受体（CAR）T细胞疗法也正在临床试验中研究，作为一种潜在治疗选择。
Hodgkin lymphoma (HL) is a rare type of lymphoma with unique histologic, immunophenotypic, and clinical features. It represents approximately one-tenth of lymphomas diagnosed in the United States and consists of two subtypes: classical Hodgkin's lymphoma (cHL), which accounts for majority of HL cases, and nodular lymphocyte predominant Hodgkin lymphoma represent approximately 5% of Hodgkin lymphoma cases. From this point, we will be focusing on cHL in this review. In general, it is considered a highly curable disease with first-line chemotherapy with or without the addition of radiotherapy. However, there are patients with disease that relapses or fails to respond to frontline regimens and the standard treatment modality for chemo sensitive cHL is high dose chemotherapy followed by autologous hematopoietic stem cell transplant (AHSCT). In recent years, targeted immunotherapy has revolutionized the treatment of cHL while many novel agents are being explored in addition to chimeric antigen receptor (CAR) T-cell therapy which is also being investigated in clinical trials as a potential treatment option.
MEMBER ACCOUNT
登录成功会直接打开下一页。
